Bristol-Myers Squibb Buys Medarex: Adds Eighth ‘Pearl' To String
Bristol sees Medarex acquisition as a way to expand its immunology and oncology pipeline in preparing for Plavix generics in 2012.
Bristol sees Medarex acquisition as a way to expand its immunology and oncology pipeline in preparing for Plavix generics in 2012.